Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.50    2.50 (3.57%)
Bid:
71.00
Ask:
74.00
Spread: 3.00 (4.225%)
Market Cap: £329.95m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Final Results

24 Aug 2005 07:00

Readybuy PLC24 August 2005 READYBUY PLCPRELIMINARY RESULTSYear ended 30 April 2005 CHAIRMAN'S STATEMENT Results Our results for the year ended 30 April 2005 show turnover of Β£313,000 (2004:Β£19,000) and operating losses of Β£252,000 (2004: Β£343,000). Furthermore, as theboard has decided to withdraw from food manufacturing, additional provisions ofΒ£804,000 have been made at the year-end. These relate to the write-off ofgoodwill and the write-down of machinery values. Although some progress was made during the year and several listings wereachieved, the level of business was not sufficient to maintain a viablemanufacturing unit. Since the year-end, the manufacturing unit has been closed and the machinery hasbeen sold. Paul Bennett, the Chief Executive, left the company on 22 July and we wish tothank him for his efforts in trying to build the business. The board is now considering the options available to the Group and will updateshareholders in due course. I would like to thank all the employees for their hard work during the difficulttrading period Colin DaviesChairman24 August 2005 READYBUY PLC CONSOLIDATED PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 30 APRIL 2005 Audited Audited 01/05/04 to 30/04/05 01/05/03 to 30/04/04 Β£000's Β£000'sTurnover 313 19 Operating Loss (252) (343) Provision for loss on operations to be discontinued (804) - (1056) (343)Interest Payable (4) (6)Interest Receivable 2 6 Loss before Taxation (1058) (343) Taxation (45) 45 Loss after taxation (1103) (298)Dividends - -Deficit for the year (1103) (298) Loss Per Share (note 3) (6.1p) (2.2p) The Group's trading activities were terminated in July 2005, therefore all ofthe above activities are classified as discontinued. READYBUY PLC CONSOLIDATED BALANCE SHEET AT 30 APRIL 2005 Audited Audited 30 April 2005 30 April 2004 Β£000's Β£000'sFixed AssetsIntangible Assets - 646Tangible Assets - 218 - 864Current AssetsStocks 2 7Debtors 44 82Cash at Bank and in Hand 169 429 215 518 Creditors: amounts due within one year (194) (323) Net current assets 21 195Total assets less current liabilities 21 1059Creditors: amounts falling due after more than one year - (25) Net Assets 21 1034 Share Capital and ReservesCalled up Share Capital 93 90Share Premium Account 1329 1242Profit and Loss Account (1401) (298) Equity and Non-Equity Shareholders' funds 21 1034 READYBUY PLC CONSOLIDATED CASHFLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2005 Audited Audited 01/05/04 to 30/04/05 01/05/03 to 30/04/04 Β£000's Β£000's Net Cash outflow from operating activities (80) (407) Returns on investments and servicing of financeInterest Paid (4) (6)Interest Received 2 6Net Cash Inflow/(Outflow) from servicing of (2) -Finance Capital Expenditure Payments to acquire tangible assets (9) (77)Sale of tangible assets 1 35 Net Cash outflow from Capital Expenditure (8) (42) Purchase of Subsidiary undertaking - (272)Net overdraft acquired with subsidiary undertaking - (6)Net Outflow from acquisitions - (278) Net Cash outflow before use of (90) (727)liquid resources and financing Financing Issue of equity Share Capital 90 1169Capital element of lease payments (34) (19)Repayment of term loans - (220)Net Inflow from financing 56 930 (Decrease)/Increase in Cash (34) 203 READYBUY PLCFOR THE YEAR ENDED 30 APRIL 2005 Notes 1. The preliminary financial results for the year ended 30 April 2005 were approved by the Directors on 24 August 2005. 2. There were no recognised gains or losses other than the result for the period. 3. The calculation of earnings per share is based upon the loss after taxation of Β£1,103,000 (2004: Β£298,000) divided by the weighted average number of ordinary shares in issue during the year which was 18,066,870 (2004: 13,585,434). 4. The preliminary statement is available from the Company's registered office at: Television House, 10-12 Mount Street, Manchester, M2 5NT. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.